AMERICAN SOCIETY OF NEPHROLOGY STRONGLY SUPPORTS CONGRESSIONAL OVERSIGHT OF TRANSPLANT SYSTEM

The American Society of Nephrology (ASN) supports efforts by Congress to improve the US transplant system. Today, the Senate Finance Committee will conduct an oversight hearing, A System in Need of Repair: Addressing Organizational Failures of the U.S.’s Organ Procurement and Transplantation Network (OPTN).

Mayo Clinic study confirms living kidney donor surgery is low risk for most patients

The risk of major complications for people who donate a kidney via laparoscopic surgery is minimal. That is the conclusion of a 20-year Mayo Clinic study of more than 3,000 living kidney donors. Only 2.5% of patients in the study experienced major complications, and all recovered completely.

“Lungs in a Box” Now Offered at Northwestern Medicine

Due to COVID-19 and a rapidly expanding list of conditions for which lung transplantation can be lifesaving, the need for new organs is growing. However, there’s a global shortage of donated lungs, which results in numerous deaths among patients on the waitlist. To help expand the donor pool, Northwestern Medicine is now using a device from XVIVO called XPS™ which is used for ex vivo lung perfusion (EVLP) – nicknamed “lungs in a box” – to rescue potentially viable lungs and those initially deemed “unacceptable” for transplant. Out of all solid organs, lungs have the lowest utilization, with only one in five donated lungs getting transplanted.

Expert Alert: 5 ways patients who are immunocompromised can protect themselves from COVID-19

As families prepare to gather later this month for Thanksgiving, it is important for patients who are immunocompromised to take extra steps to protect themselves from becoming infected with COVID-19. People who are immunocompromised have weakened immune systems, which means they have a higher risk of becoming severely ill from COVID-19.

World-first COVID vaccine booster randomized clinical trial in transplant patients proves third shot is very effective

The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo.
The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group – after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.

World-first COVID vaccine booster randomized clinical trial in transplant patients proves third shot is very effective

The study enrolled 120 transplant patients between May 25th and June 3rd. None of them had COVID previously and all of them had received two doses of the Moderna vaccine. Half of the participants received a third shot of the vaccine (at the 2-month mark after their second dose) and the other half received placebo. The primary outcome was based on antibody level greater than 100 U/ml against the spike protein of the virus. In the placebo group – after three doses (where the third dose was placebo), the response rate was only 18% whereas in the Moderna three-dose group, the response rate was 55%.

Monoclonal antibody therapy for COVID-19 safe, effective for transplant patients

Treating transplant patients with mild to moderate cases of COVID-19 with monoclonal antibodies is safe and helps prevent serious illness, according to a Mayo Clinic study recently published in Open Forum Infectious Diseases. These results are especially important because transplant patients who are infected with COVID-19 have a higher risk of severe illness and death.

Announcing Virtual Press Conference for Experimental Biology 2021 Meeting

Reporters are invited to join a live Q&A discussion of exciting research announcements at the forefront of the life sciences during a virtual press conference for the Experimental Biology (EB) 2021 meeting. The press conference will be held online from 1–1:45 p.m. EDT on Monday, April 26, 2021 (RSVP by Friday, April 23).

Reverse-order heart-liver transplant helps prevent rejection for highly sensitized patients

Patients with high levels of antibodies face major challenges getting a transplant. These highly sensitized patients have a higher risk of death while waiting for suitable organs. But there is new hope for highly sensitized patients in need of a combined heart and liver transplant, thanks to an innovative surgical approach at Mayo Clinic.

Lung, Heart, Kidney and Liver Transplant Programs Rank among Nation’s Best

UC San Diego Health’s lung, heart, kidney and liver transplant programs rank at the top nationally in the latest biannual Scientific Registry of Transplant Recipients (SRTR) report. Innovative treatment and multi-disciplinary care contribute to the high rankings for one-year survival outcomes.

Synthetic Biology and Machine Learning Speed the Creation of Lab-Grown Livers

Researchers at the University of Pittsburgh School of Medicine have combined synthetic biology with a machine learning algorithm to create human liver organoids with blood and bile handling systems. When implanted into mice with failing livers, the lab-grown replacement livers extended life.

Mayo Clinic heart transplant program recognized for top patient outcomes

The Mayo Clinic heart transplant program in Arizona has been recognized as one of the top transplant programs in the U.S. based on quality and patient outcomes. The Scientific Registry of Transplant Recipients, a national medical database that evaluates solid organ transplantation in the U.S., has reported that the Mayo program has achieved the top long-term outcomes in the country.

UC San Diego Health Revives Non-Beating Donor Heart for Successful Transplantation

UC San Diego Health is the first hospital on the West Coast to perform heart transplant surgery from a donor after circulatory death using a new portable organ care system. The investigational procedure could significantly decrease transplant waiting list times and improve patient outcomes.

Severely Damaged Human Lungs Can Now Be Successfully Recovered

A multidisciplinary team from Columbia Engineering and Vanderbilt University has now demonstrated that severely injured donor lungs that have been declined for transplant can be recovered outside the body by a system that uses cross-circulation of whole blood between the donor lung and an animal host. For the first time, a severely injured human lung that failed to recover using the standard clinical EVLP was successfully recovered during 24 hours on the team’s cross-circulation platform.

Study Finds Immune Cell That Predicts Risk of Organ Rejection In Transplant Patients

Researchers at The Ohio State University College of Medicine are the first to identify an immune cell that may predict a transplant patient’s risk of developing antibodies that can cause organ rejection. This discovery could lead to the development of therapies to prevent complications after transplant surgery.

Certain liver cells may help prevent organ rejection after transplant and other conditions, study finds

Mesenchymal stromal cells from fat tissue and bone marrow are widely used in therapeutic trials for their anti-inflammatory qualities, but new Mayo Clinic research finds that liver cells may be of greater value.

The study, published in Liver Transplantation, finds that liver mesenchymal stromal cells have immunoregulatory qualities that make them more effective than similar cells derived from adipose, or fat, tissue and bone marrow.